Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2

Lim CE., Pasternak B., Eliasson B. et al.

DOI : https://doi.org/10.57105/2415-7252-2024-2-01

Abstract

Aims/hypothesis
Our aim was to assess treatment discontinuation, reinitiation and switching between drugs within the same drug class for glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes.
Methods
We used data from nationwide registers in Sweden to perform separate analyses for all patients with type 2 diabetes who filled a first prescription of a GLP-1 receptor agonist or an SGLT2 inhibitor between 2017 and 2021. Patients were considered to be on treatment for the period during which prescriptions were refilled before the estimated end date of the most recent prescription, including a 90-day grace period, i.e. the time allowed between and after prescriptions before treatment is considered as discontinued. We used the Aalen–Johansen estimator to estimate cumulative incidences of discontinuation and reinitiation, and Fine–Gray sub-distribution hazard models to assess the association of clinical variables with the risk of discontinuation.
Results
Among 73,895 new users of GLP-1 receptor agonists, the cumulative incidence of treatment discontinuation was 23.6 % at 1 year and 38.5 % at 3 years. Among patients who discontinued, the cumulative incidence of treatment reinitiation was 41.1 % at 1 year and 57.4 % at 3 years after discontinuation. Among 113,207 new users of SGLT2 inhibitors, the cumulative incidence of treatment discontinuation was 27.9 % at 1 year and 45.9 % at 3 years, with a cumulative incidence of reinitiation of 40.4 % at 1 year and 55.7% at 3 years after discontinuation. When varying the grace period between 60 days and 365 days, treatment discontinuation rates at 3 years ranged from 23.3 % to 43.6 % among GLP-1 receptor agonist users and from 28.8 % to 50.6 % among SGLT2 inhibitor users. The proportion of patients who had ongoing treatment, regardless of previous discontinuation episodes, ranged between approximately 70 % and 80 % for both drugs during a 1–5 year period after treatment initiation across analyses using various grace periods. In terms of switching, 22.9 % of the GLP-1 receptor agonist users and 2.1 % of the SGLT2 inhibitor users switched between drugs within the same drug class. Patient characteristics associated with treatment discontinuation were similar for GLP-1 receptor agonists and SGLT2 inhibitors, although the association between higher BMI and a lower likelihood of treatment discontinuation was stronger for GLP-1 receptor agonists.
Conclusions/interpretation
Approximately half of type 2 diabetes patients who had started using GLP-1 receptor agonists or SGLT2 inhibitors had discontinued treatment within 5 years of follow-up. However, more than half of those who discontinued treatment subsequently reinitiated treatment, such that the proportion with ongoing treatment was approximately 70–80 % for both drugs during a 1–5 year period after treatment initiation. This suggests that the proportion of patients with long-term use of the medications is larger than indicated by analyses focusing on treatment discontinuation. Patient characteristics associated with treatment discontinuation were similar for GLP-1 receptor agonists and SGLT2 inhibitors.

Keywords: Adherence, Discontinuation, Drug switching, GLP-1 receptor agonists, Persistence, Proportion of patients covered, Reinitiation, SGLT2 inhibitors, Type 2 diabetes

References:

  1. American Diabetes Association Professional Practice Committee (2024) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes – 2024. Diabetes Care 47(Suppl 1):S158–S178. https://doi.org/10.2337/dc24-er07a
  2. Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43(2):487–493
  3. Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486
  4. Lim C-E, Pasternak B, Eliasson B, Danaei G, Ueda P (2022) Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol 30(8):634–643
  5. Colling C, Atlas SJ, Wexler DJ (2021) Application of 2021 American Diabetes Association glycemic treatment clinical practice recommendations in primary care. Diabetes Care 44(6):1443–1446. https://doi.org/10.2337/dc21-0013
  6. Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R (2021) Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus. J Am Heart Assoc 10(13):21084
  7. Perkovic V, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391(2):109–121. https://doi.org/10.1056/NEJMoa2403347
  8. Davies M, Færch L, Jeppesen OK et al (2021) Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971–984
  9. Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
  10. Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381(9):841–851. https://doi.org/10.1056/NEJMoa1901118
  11. Capehorn MS, Catarig AM, Furberg JK et al (2020) Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 46(2):100–109
  12. Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141
  13. Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322. https://doi.org/10.1056/NEJMoa1603827
  14. Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425–1435. https://doi.org/10.1056/NEJMoa2004967
  15. Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389
  16. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657
  17. Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306
  18. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):17–18
  19. Wettermark B, Hammar N, Fored CM et al (2007) The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726–735
  20. Eeg-Olofsson K, Åkesson K, Nåtman J et al (2022) National Diabetes Register, annual report 2021. Available from https://ndr.registercentrum.se/statistik/arsrapporter/p/Skf28_I3i. Accessed 9 Apr 2025
  21. Eeg-Olofsson K, Miftaraj M, Ann-Marie S et al (2021) National Diabetes Register, annual report 2020. Available from https://ndr.registercentrum.se/statistik/arsrapporter/p/Skf28_I3i. Accessed 9 Apr 2025
  22. Gudbjörnsdottir S, Miftaraj M, Svensson A-M et al (2020) National Diabetes Register, annual report 2019. Available from https://ndr.registercentrum.se/statistik/arsrapporter/p/Skf28_I3i. Accessed 9 Apr 2025
  23. Gudbjörnsdottir S, Svensson A-M, Eliasson B et al (2019) National Diabetes Register, annual report 2018. Available from https://ndr.registercentrum.se/statistik/arsrapporter/p/Skf28_I3i. Accessed 9 Apr 2025
  24. Gudbjörnsdottir S, Svensson A-M, Eliasson B et al (2018) National Diabetes Register, annual report 2017. Available from https://ndr.registercentrum.se/statistik/arsrapporter/p/Skf28_I3i. Accessed 9 Apr 2025
  25. Ludvigsson JF, Andersson E, Ekbom A et al (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11(1):1–16
  26. Ludvigsson JF, Almqvist C, Bonamy AKE et al (2016) Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31(2):125–136. https://doi.org/10.1007/s10654-016-0117-y
  27. Rubin D (1987) Multiple imputation for nonresponse in surveys. Wiley, New York
  28. Lim MT, Ab Rahman N, Teh XR et al (2021) Optimal cut-off points for adherence measure among patients with type 2 diabetes in primary care clinics: a retrospective analysis. Ther Adv Chronic Dis 12:2040622321990264. https://doi.org/10.1177/2040622321990264
  29. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC (2009) Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 25(9):2303–2310. https://doi.org/10.1185/03007990903126833
  30. Loucks J, Zuckerman AD, Berni A, Saulles A, Thomas G, Alonzo A (2022) Proportion of days covered as a measure of medication adherence. Am J Health Syst Pharm 79(6):492–496. https://doi.org/10.1093/ajhp/zxab392
  31. Rasmussen L, Pratt N, Hansen MR, Hallas J, Pottegård A (2018) Using the “proportion of patients covered” and the Kaplan-Meier survival analysis to describe treatment persistence. Pharmacoepidemiol Drug Saf 27(8):867–871. https://doi.org/10.1002/pds.4582
  32. Malik ME, Falkentoft AC, Jensen J et al (2023) Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. Lancet Reg Health Eur 29:100617
  33. O’Hara DV, Janse RJ, Fu EL, Jardine MJ, Carrero J-J (2024) Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care. Diabetes Res Clin Pract 213:111745
  34. Svensson AM, Toll A, Lebrec J, Miftaraj M, Franzén S, Eliasson B (2021) Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden. Diabetes Obes Metab 23(3):720. https://doi.org/10.1111/dom.14276
  35. de Germay S, Pambrun E, Pariente A, Grenet G, Bezin J, Faillie JL (2024) Use of sodium-glucose cotransporter-2 inhibitors in France: analysis of French nationwide health insurance database. Diabetes Obes Metab 26(5):1678–1686. https://doi.org/10.1111/dom.15472
  36. Lassen MCH, Johansen ND, Modin D et al (2024) Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: a nationwide registry study. Diabetes Obes Metab 26(11):5239–5250. https://doi.org/10.1111/dom.15872
  37. Uzoigwe C, Liang Y, Whitmire S, Paprocki Y (2021) Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting. Diabetes Ther 12(5):1475–1489. https://doi.org/10.1007/s13300-021-01053-7
  38. Polonsky WH, Arora R, Faurby M, Fernandes J, Liebl A (2022) Higher rates of persistence and adherence in patients with type 2 diabetes initiating once-weekly vs daily injectable glucagon-like peptide-1 receptor agonists in US clinical practice (STAY study). Diabetes Ther 13(1):175–187. https://doi.org/10.1007/s13300-021-01189-6
  39. Mody R, Yu M, Nepal B, Konig M, Grabner M (2021) Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data. Diabetes Obes Metab 23(1):106–115. https://doi.org/10.1111/dom.14195
  40. Nagin DS, Odgers CL (2010) Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 6(1):109–138. https://doi.org/10.1146/annurev.clinpsy.121208.131413
PDF (українська)

Published
2025

How to Cite

Lim CE., Pasternak B., Eliasson B. (2025). Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2. Diabetes Obesity Metabolic Syndrome. 5(14), 22-40.